Tekla Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Tekla Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-318,833	Closed	-$507K	–	206
2018 Q4	$507K	Sell	318,833 -145,928	-31%	-$413K	0.02%	188
2018 Q3	$1.71M	Sell	464,761 -151,239	-25%	-$451K	0.06%	162
2018 Q2	$1.74M	Hold	616,000	–	–	0.07%	140
2018 Q1	$2.29M	Hold	616,000	–	–	0.09%	129
2017 Q4	$1.77M	Hold	616,000	–	–	0.07%	131
2017 Q3	$2.77M	Buy	+616,000	New	+$2.74M	0.1%	106
2017 Q1	–	Sell	-443,851	Closed	-$1.83M	–	147
2016 Q4	$1.83M	Buy	+443,851	New	+$2.36M	0.08%	111
2015 Q4	–	Sell	-547,300	Closed	-$3.78M	–	164
2015 Q3	$3.78M	Hold	547,300	–	–	0.14%	114
2015 Q2	$4.85M	Hold	547,300	–	–	0.18%	86
2015 Q1	$5.4M	Buy	+547,300	New	+$6.83M	0.21%	78

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tekla Capital Management's ACHN Position: Q1 2019 in Review

Tekla Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 318,833 shares — an estimated $507K sold.

Tekla Capital Management first reported a position in ACHN in Q1 2015 and held it in 10 quarters. The position peaked at $5.4M in Q1 2015. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

Tekla Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Tekla Capital Management sold 318,833 Achillion Pharmaceuticals shares in Q1 2019, an estimated $507K.
Tekla Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Tekla Capital Management's Achillion Pharmaceuticals position peaked at $5.4M in Q1 2015.
110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.